Related Experiment Video
Updated: Jul 25, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
A heparin analogue with specific action on antithrombin III.
Lancet (London, England)
|January 15, 1977
Summary
A novel heparin analogue selectively enhances antithrombin III activity in vivo, offering potential for venous thrombosis prophylaxis. This analogue shows minimal impact on overall clotting, unlike traditional heparin.
Area of Science:
- Pharmacology
- Biochemistry
- Thrombosis Research
Background:
- Heparin is a widely used anticoagulant.
- Developing anticoagulants with improved safety profiles is crucial.
- Heparin analogues offer potential for targeted therapeutic effects.
Purpose of the Study:
- To compare the in vivo and in vitro effects of heparin and a semi-synthetic heparin analogue.
- To evaluate the antithrombotic potential of the heparin analogue.
Main Methods:
- In vitro assays measuring heparin activity and kaolin-cephalin clotting time (K.C.C.T.).
- In vivo studies assessing antithrombin III potentiation and K.C.C.T. after parenteral administration.
- Comparison of heparin and its analogue.
Main Results:
- The heparin analogue showed minimal in vitro effect on specific heparin assays and K.C.C.T. compared to heparin.
- In vivo, the analogue significantly potentiated antithrombin III, similar to heparin.
- The heparin analogue did not significantly affect K.C.C.T. in vivo.
Conclusions:
- The heparin analogue selectively potentiates antithrombin III in vivo.
- This selective action suggests a potentially favorable profile for venous thrombosis prophylaxis.
- The analogue may offer antithrombotic benefits with reduced impact on global coagulation parameters.
Related Concept Videos
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...